COMPOSITION COMPRISING ANTIMICROBIAL METAL IONS AND A QUATERNARY CATIONIC SURFACTANT
20220030875 · 2022-02-03
Inventors
Cpc classification
A61P31/00
HUMAN NECESSITIES
A61K9/06
HUMAN NECESSITIES
A61K31/198
HUMAN NECESSITIES
A61P17/02
HUMAN NECESSITIES
A61K31/14
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
A01N37/44
HUMAN NECESSITIES
A61K31/14
HUMAN NECESSITIES
A01N2300/00
HUMAN NECESSITIES
A01N2300/00
HUMAN NECESSITIES
A61K31/198
HUMAN NECESSITIES
A61K9/0014
HUMAN NECESSITIES
International classification
A01N37/44
HUMAN NECESSITIES
A61K31/14
HUMAN NECESSITIES
A61K31/198
HUMAN NECESSITIES
A61K9/00
HUMAN NECESSITIES
Abstract
The present invention relates to an antimicrobial composition suitable for use on skin and wounds comprising a source of an antimicrobial metal ion and a quaternary cationic surfactant.
Claims
1. An antimicrobial composition for treating wound bacteria in a biofilm, the composition comprising ionic silver, EDTA at a level of from 0.01% to 10% by weight, and a quaternary cationic surfactant, wherein the quaternary cationic surfactant is present at a level of more than or equal to 0.025% by weight, wherein the composition has a pH from 4 to 8, wherein the ionic silver, the EDTA, and the quaternary cationic surfactant are present in the composition in amounts that provide synergistic antimicrobial activity against the wound bacteria, and wherein the composition is in the form of a thin soluble film, the thin soluble film being suitable for lamination to a wound dressing.
2. A composition as claimed in claim 1, wherein the ionic silver is present at a level of from 0.00001% to 1.0% by weight of the composition.
3. A composition as claimed claim 1, wherein the cationic surfactant is selected from a group of the salts where the cation is benzethonium, benzalkonium, dimethyldiakylonium, alkylpyridinium and alkyltrimethylammonium.
4. A composition as claimed in claim 1, wherein the quaternary cationic surfactant is present at a level of from 0.05% to 4% by weight.
5. A composition as claimed in claim 1, wherein the EDTA is present as a di-, tri- or tetra-basic salt of EDTA.
6. A composition as claimed in claim 1, wherein the EDTA is present in the composition at a level of 0.1% to 4% by weight of the composition.
7. A process for making an antimicrobial wound dressing comprising: (i) obtaining an absorbent wound dressing, and (ii) treating the wound dressing with an antimicrobial composition in the form of a thin soluble film, the thin soluble film being laminated to the wound dressing and for treating wound bacteria in a biofilm, wherein the composition comprises ionic silver, EDTA at a level of from 0.01% to 10% by weight, and a quaternary cationic surfactant, wherein the quaternary cationic surfactant is present at a level of more than or equal to 0.025% by weight, wherein the composition has a pH from 4 to 8, and wherein the ionic silver, the EDTA, and the quaternary cationic surfactant are present in the composition in amounts that provide synergistic antimicrobial activity against the wound bacteria.
8. A composition as claimed in claim 1, wherein the quaternary cationic surfactant is selected from benzethonium chloride and benzalkonium chloride.
9. A composition as claimed in claim 1 having a pH from 4.5 to 5.5.
10. A composition as claimed in claim 1, wherein the quaternary cationic surfactant is present at a level of from 0.5% to 2% by weight.
11. A composition as claimed in claim 1, wherein the EDTA is present in the composition at a level of 0.2% to 1% by weight.
12. A composition as claimed in claim 1, having a pH of about 5.5 to protect peri-wound tissue by not altering its pH balance.
13. A process as claimed in claim 12, wherein the composition has a pH from 4.5 to 5.5.
14. A process as claimed in claim 12, wherein the composition has a pH of about 5.5 to protect peri-wound tissue by not altering its pH balance.
15. A process as claimed in claim 12, wherein the EDTA is present in the composition at a level of 0.2% to 1% by weight.
Description
[0020]
[0021]
[0022]
EXAMPLE 1
[0023] Quaternary Cationic Surfactant Enhancement of Silver Efficacy
[0024] Method: The MBEC Assay System using the Calgary Biofilm Device provides an assay for screening antibiotics and biocides for activity against bacterial biofilms. The system involves a reactor for the formation of 96 equivalent biofilms. The MBEC Assay System is suited to determination of MBEC values (Minimum Biofilm Eradication Concentration) and other related values. A description of the system and method is given in “The MBEC Assay System: Multiple Equivalent Biofilms for Antibiotic and Biocide Susceptibility Testing” by Howard Ceri, Merle Olson, Douglas Morck, Douglas Storey, Ronald Read,
[0025] Andre Buret and Barbara Olson, 2001 Methods in Enzymology Vol 337, [25] p 377 and “The Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms” Ceri, Olson, Stremick, Read, Morck and Buret Journal of Clinical Microbiology, June 1999, Vol 37, No. 6, p 1771-1776.
[0026] Biofilms were grown on the pegs of 96-well plate lids (Nunc-TSP parts 445497 and 167008, Thermo Fisher Scientific Inc); these were then thoroughly rinsed in purified water. Into a fresh plate, using aseptic techniques and filter sterilised solutions, aliquots of an aqueous silver nitrate solution, various quaternary cationic surfactant aqueous solutions and purified water were pipetted to give a matrix of 10411 test samples of various silver and surfactant concentrations. The biofilm covered plate lids were then replaced and left in contact with the test solution for either 30 minutes, 2 or 4 hours. After this time the lids were removed and any residual test agent was removed from the pegs by rinsing in sterile normal saline solution (0.85% wlw NaCl). The residual biofilms were then physically removed from the pegs by the established sonication method. The released and still viable bacteria where then grown-on in their planktonic form for 24 hours in a new plate in which the wells contained a growth medium. The concentration of surviving bacteria released from the pegs was then estimated by turbidity measurement on an optical plate reader. Although optical densities were recorded, a simple grey scale representation was adequate for interpretation.
[0027] Tested silver ion concentrations ranged from 1.625 μg/ml to 200 μg/ml, doubling in concentration between successive samples. The cationic surfactants tested were benzethonium benzalkonium chloride, dimethyldialkylammonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride at concentrations ranging from 31.25 μg/ml to 200011 g/till also doubling in concentration between successive samples.
[0028] Results: The results are presented by the charts in
[0029] These results show the concentration ranges where synergy was observed. All cationic surfactants assayed showed synergy with ionic silver above a specific critical concentration for each surfactant. Below this critical concentration inhibition of the antimicrobial effect of silver ions was observed.
EXAMPLE 2
[0030] EDTA and Quaternary Cationic Surfactant Enhancement of Silver Efficacy
[0031] Method: As Example 1 but with each test solution also containing 0.25% w/w di-sodium ethyl enediaminetetra-acetic acid salt.
[0032] Results: The results are presented in
[0033] These results show that EDTA further enhances the synergistic antimicrobial activity of the cationic surfactant and the metal ion.
EXAMPLE 3
[0034] Enhancement of Antimicrobial Efficacy of Examples of Silver Containing Wound Dressings
[0035] The depth to which an antimicrobial effect on an agar gel containing Staphylococcus aureus was assessed for different types of treated and untreated silver containing wound dressings.
[0036] Materials:
[0037] Test Dressings: [0038] AQUACEL Ag (5×5 cm), batch 9L019035, absorbent, gelling, fibrous-felt dressing containing 1.2% w/w ionic silver. [0039] Allevyn Ag Non-adhesive, batch 0935, absorbent foam dressing containing silver sulphadiazine. [0040] Silvercel Hydro-alginate, batch, 37923, a dressing comprised of a mixed alginate and silver-coated nylon fibrous pad wrapped in a perforated ethylene methyl acrylate film. [0041] Sorbsan Silver—Plus, batch 012035, an absorbent nonwoven alginate pad impregnated with silver, bonded to a secondary absorbent viscose layer. [0042] All of the above treated with di-sodium EDTA and benzethonium chloride. [0043] Microbiological Media: [0044] Maximal Recovery Diluent (MRD) [0045] Pre-dried Tryptone Soy Agar (TSA) plates [0046] 0.85% Saline Solution [0047] Molten Tryptone Soy Agar (TSA) [0048] Industrial Denatured Alcohol (IDA) [0049] Sterile Deionised Water (SDW) [0050] Microbial Challenge: Staphylococcus aureus NCIMB 9518
[0051] Methods: Two 3.75 cm diameter circular samples were aseptically cut from each dressing. One of each sample was placed into a sterile Petri dish for later testing. The remaining sample was treated with a solution according to the invention using the following procedure: —0.25 grams each of di-sodium EDTA and benzethonium chloride were weighed into separate sterile bottles and dissolved in 100 ml of 50:50 (v/v) IDA:SDW and 100% IDA respectively. 50 μg/cm.sup.2 of EDTA and 50 fig/cm.sup.2 of benzethonium chloride were added to the dressing by carefully pipetting 220 μl of each solution over the entire surface of each dressing sample. The samples were then placed back into the original packaging and dried in a vacuum oven at 90° C. and 0.9 atmospheres of vacuum for approximately 2 hours.
[0052] A colorimeter was used to prepare a suspension of Staphylococcus aureus approximately 1×10.sup.8 CFU/ml in MRD (0.16-0.18 OD540) and serially diluted to obtain approximately 1×10.sup.4 CFU/ml. Two 100 ml volumes of molten TSA (approximately 45° C.) were each inoculated with 1 ml of the 1×10.sup.4 CFU/ml Staphylococcus aureus suspension and swirled to mix. 20 ml volumes of this bacterially seeded molten agar were then measured and poured into nine 60 ml pots (with an internal diameter of 3.75 cm). When cooled and set these pots were incubated at 35° C.±3° C. for 4 hours±15 minutes to initiate growth. After 4 hours each of the test dressing was hydrated with 2.5 ml of 0.85% Saline Solution in a sterile Petri dish and placed into a 60 ml pot and onto the surface of the seeded agar. One pot had no dressing applied to act as a positive control. The pots were then incubated for another 24 hours after which time the dressings were removed and disposed of. The pots were then re-incubated for a minimum 72 hours to allow the already established colonies to grow. After the final incubation period the pots were evaluated and photographed next to a calibrated rule.
[0053] Results: Where the dressing had imparted an antibacterial effect in the seeded agar beneath the dressing the agar appeared transparent. Where bacterial growth had not been inhibited the agar appeared opaque. The depth of the transparent zone of agar from the surface in contact with the dressing was interpreted as an indication of antimicrobial efficacy. Results are presented in
[0054] The addition of this example formulation of the invention increased the depth of the transparent zone by at least a factor of two for all dressing types but the rank order remained the same. This suggested that potency is dependent on dressing type but synergystic enhancement was independent of dressing type.
[0055] The Aquacel Ag had a greater depth of penetration than the other dressings for both the control and treated tests. Aquacel Ag also had the greatest improvement in antimicrobial penetration when treated with a solution according to the invention as the average depth of penetration was three times greater than the control.
EXAMPLE 4
[0056] Enhancement of Antimicrobial Efficacy with Different Antimicrobial Metals
[0057] Previous Examples using the MBEC (Minimum Biofilm Eradication Concentration) method have shown that the addition of specific antimicrobial agents to silver enhances its antimicrobial activity. The purpose of this example was to assess the effect of these agents on the antimicrobial activity of other metals, using the MBEC method.
[0058] Method: A 0.2% w/w aqueous stock solution of the quaternary cationic surfactant didecyl dimethyl ammonium chloride (DDAC) was prepared from a concentrated commercial solution (50% w/v solution, Merck KGaA, Darmstadt, Germany). Individual stock solutions of silver nitrate, copper (II) nitrate trihydrate, gallium (III) nitrate, nickel (II) nitrate hexahydrate, zinc sulphate heptahydrate, manganese (II) chloride tetrahydrate, iron (II) sulphate heptahydrate, iron (III) sulphate hydrate, and copper (II) nitrate trihydrate were prepared from commercially available laboratory solids. Each solution was adjusted to approximately pH 5.5 by the addition of small amounts of dilute aqueous sodium hydroxide and/or dilute hydrochloric acid. The metal ion solutions were then volumetrically diluted to 0.1% w/w (with respect to the metal) with purified water. Any precipitates were kept homogenously suspended by vigorous shaking. The MBEC assay as described in Example 1 was then performed for the surfactant solution alone, each individual metal ion solution and then for each metal solution in combination with the surfactant solution.
[0059] Results:
TABLE-US-00001 MBEC for the metal ion (ppm) t Without With 0.1% Metal pH DDAC DDAC Synergy Silver 5.27 12.5 0.097 +ve Copper * 5.47 15.6 1.95 +ve Iron (II) * 5.30 >1000 ≤0.24 +ve Iron (III) * 5.40 >1000 ≤0.24 +ve Gallium * 5.51 >1000 ≤0.24 +ve Manganese 5.40 >1000 ≤0.24 +ve Nickel 5.51 >1000 ≤0.24 +ve Zinc 5.40 >1000 ≤125 +ve DDAC — 0.2% -na- -na- † Lowest concentration at which activity was observed; ppm is equivalent to μg/g (or μg/ml in aqueous solutions). These values are approximate. * These metals formed precipitates when the 0.1% solutions were pH adjusted to pH 5.5; however the precipitate was dissolved when diluted in the test plate.
[0060] Literature data for metal solutions (pH unadjusted) suggests the following order in terms of antimicrobial activity: [0061] Silver>Iron>Nickel>Copper>Gallium>Magnesium>Bismuth
[0062] The MBEC for DDAC alone was determined as approximately 0.2%. When 0.1% DDAC was used in combination with the listed metal ion solutions all produced a significant reduction in the MBEC for the metal thus demonstrating a synergistic effect which is independent of the identity of antimicrobial metal used.
EXAMPLE 5
[0063] The Effect of pH
[0064] When used at high concentration many cationic surfactants have antimicrobial activity; typically this is enhanced by an alkaline pH. Similarly, many researchers have found that the activity of some silver compounds is also enhanced by elevated pH. To prevent pain and tissue damage, products applied to broken skin need to be near pH neutral or have slightly acidic in pH. This Example investigates the effect of pH on the synergystic effect between a quaternary cationic surfactant and an antimicrobial metal.
[0065] Method: The following aqueous stock solutions were prepared: —benzethonium chloride (1.0% w/w), silver nitrate (0.1% w/w with respect to the metal), sodium acetate (0.5M) and acetic acid (0.5M).
[0066] In the control experiment sodium acetate and acetic acid solutions were mixed at various ratios and diluted with purified water to give a range of pH buffer solutions with different pH's but with the same overall ionic strength (0.1M with respect to acetate ion). To each, sufficient silver nitrate solution was added to make the solution 0.01% w/w with respect to silver. Each solution was then challenged in the MBEC method as described in Example 1 to determine if, at this level of pH and silver, the solution was above or below the MBEC.
[0067] Using a second set of similarly prepared solutions (0.1M acetate buffer, 0.01% silver) a second MBEC experiment was performed in which the concentration of the surfactant solution was varied.
[0068] Results: None of the 0.01% silver solutions pH buffered in the range 4.7 to 7.7 were effective against biofilms in the MBEC model. Surfactant concentrations of >0.25%, 5_ 0.10% and 0.025% were required to eradicate biofilm in the MBEC model at pH 6.9, 6.2 and 5.5 respectively.
[0069] This suggests the synergystic antimicrobial effect of the current invention is enhanced by reducing pH (becoming more acidic) which is counter to current wisdom.
EXAMPLE 6
[0070] Enhancement of the Antimicrobial Efficacy of a Semi-Solid (Gel) Composition Containing Silver, EDTA and Quaternary Surfactant
[0071] Previous Examples (1, 2, 4 & 5) illustrate applicability to simple solutions. This example seeks to demonstrate that the addition of inert excipients that modify the physical form and properties of the base active solution have no effect on the observed efficacy. Increasing the viscosity by the addition of the gelling agent hydroxyethylcellulose (HEC, Aqualon type: Natrosol 2501{X Pharm) is used in this example with the activity of the formulated gels being compared to the equivalent solution using the MBEC assay as previously described.
[0072] Method: Stock solutions of silver nitrate, benzethonium chloride, di-sodium EDTA (pH ˜4), tri-sodium EDTA (pH ˜8) and HEC were prepared. These were then combined in various ways to produce a matrix of samples of one, two, three components (EDTA being included only once in any combination) with and without HEC. The final component concentrations being 0%, 0.0001% or 0.02% for silver (Ag); 0%, 0.1% or 1% for benzethonium chloride (BeCl); 0%, 0.2% or 1% for EDTA; 0% or 0.1% for HEC. Test samples were challenged against a microbial biofilm using the MBEC method previously outlined in Example 1. The results were recorded as either effective (no bacterial growth) or ineffective (bacterial growth as indicated by turbidity). All test samples were prepared in duplicate and each MBEC determination was performed in triplicate therefore six assays results were obtained for each sample.
[0073] Results:
[0074] A summary of the results for combinations are shown in